We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.
Corinna Sorenson, PhD, MHSA, MPH
Advertisement
Articles by Corinna Sorenson, PhD, MHSA, MPH
Advertisement
Latest Updated Articles
- Value-Based Arrangements May Be More Prevalent Than Assumed
February 13th 2019
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
5